Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
In one aspect, methods of treating hyperinsulinemic hypoglycemia comprising administration of an effective amount of a derivative of an exendin-4 peptide are provided. In some embodiments, the method comprises subcutaneously administering to a patient having hyperinsulinemic hypoglycemia a therapeutically effective amount of exendin(5-39).
1. A method of treating hyperinsulinemic hypoglycemia, the method comprising administering an exendin-4 derivative to a patient in need thereof, wherein the exendin-4 derivative is selected from the group consisting of exendin(3-39), exendin(4-39), exendin(5-39), exendin(6-39), exendin(7-39), and exendin(8-39), and wherein the exendin-4 derivative is administered at a dose of 0.01 mg to 50 mg.
2. The method of claim 1 , wherein the exendin-4 derivative is exendin(5-39).
3. The method of claim 1 , wherein the exendin-4 derivative is pegylated.
4. The method of claim 1 , wherein the exendin-4 derivative is subcutaneously administered.
5. The method of claim 1 , wherein the patient has previously had bariatric surgery.
6. The method of claim 5 , wherein the patient has previously had a bariatric surgery selected from the group consisting of Roux-en Y gastric bypass, vertical sleeve gastrectomy, placement of an endosleeve device, duodenal mucosal resurfacing, partial bypass of the duodenum, vagal nerve blockade, and pyloroplasty.
7. The method of claim 1 , wherein the patient has previously had gastrointestinal surgery.
8. The method of claim 1 , wherein the patient has congenital hyperinsulinemic hypoglycemia.
9. The method of claim 1 , wherein the exendin-4 derivative is administered at a dose of 0.5 mg to 30 mg.
10. The method of claim 1 , wherein the exendin-4 derivative is administered at a dose of 0.01 mg to 1 mg.
11. The method of claim 1 , wherein the exendin-4 derivative is administered once per day.
12. The method of claim 1 , wherein the exendin-4 derivative is administered twice per day.
13. The method of claim 1 , wherein the exendin-4 derivative is administered once per week or twice per week.
14. The method of claim 1 , wherein the exendin-4 derivative is exendin(5-39) and wherein the exendin(5-39) is subcutaneously administered at a dose of 0.5 mg to 30 mg twice per day (BID).
15. The method of claim 1 , wherein the exendin-4 derivative is exendin(5-39) and wherein the exendin(5-39) is subcutaneously administered at a dose of 0.1 mg to 1 mg twice per day (BID).
16. The method of claim 1 , wherein the exendin-4 derivative is a pegylated exendin(5-39) and wherein the pegylated exendin(5-39) is subcutaneously administered at a dose of 0.5 mg to 30 mg once per week (QW) or twice per week (BIW).
17. The method of claim 1 , wherein the exendin-4 derivative is a pegylated exendin(5-39) and wherein the pegylated exendin(5-39) is subcutaneously administered at a dose of 0.1 mg to 1 mg once per week (QW) or twice per week (BIW).